Cargando…
Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2
BACKGROUND: Vasohibin 2 (VASH2) has previously been identified as an agiogenenic factor and a cancer related protein. Here we investigated the association of VASH2 expression and chemoresistance in pancreatic cancer. METHODS: Immunohistochemical staining for VASH2 was performed on 102 human pancreat...
Autores principales: | Tu, Min, Li, Haifeng, Lv, Nan, Xi, Chunhua, Lu, Zipeng, Wei, Jishu, Chen, Jianmin, Guo, Feng, Jiang, Kuirong, Song, Guoxin, Gao, Wentao, Miao, Yi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5360034/ https://www.ncbi.nlm.nih.gov/pubmed/28327155 http://dx.doi.org/10.1186/s12943-017-0619-6 |
Ejemplares similares
-
Vasohibin-2 promotes proliferation in human breast cancer cells via upregulation of fibroblast growth factor-2 and growth/differentiation factor-15 expression
por: TU, MIN, et al.
Publicado: (2014) -
Transactivation of proto-oncogene c-Myc by hepatitis B virus transactivator MHBs(t167)
por: LUN, YONG-ZHI, et al.
Publicado: (2014) -
MiR200-upregulated Vasohibin 2 promotes the malignant transformation of tumors by inducing epithelial-mesenchymal transition in hepatocellular carcinoma
por: Xue, Xiaofeng, et al.
Publicado: (2014) -
Inhibition of CHK1 sensitizes Ewing sarcoma cells to the ribonucleotide reductase inhibitor gemcitabine
por: Goss, Kelli L, et al.
Publicado: (2017) -
Undifferentiated Carcinoma of Pancreas with Osteoclast-Like Giant Cells: One Center’s Experience of 13 Cases and Characteristic Pre-Operative Images
por: Gao, Yong, et al.
Publicado: (2022)